1-Methyl-7-oxa-1-azaspiro[3.4]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: 1-Methyl-7-oxa-1-azaspiro[3.4]octane
• 英文别名: 1-methyl-7-oxa-1-azaspiro[3.4]octane
• 化学式: C₇H₁₃NO
• 分子量: 127.18
• InChiKey: RYHTYCVPVWFJBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US20140235634A1

  公开（公告）日：2014-08-21

  Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.

  本文描述了公式（I）或公式（VI）的化合物，其药学上可接受的盐以及其药物组合物。还提供了包含公式（I）或公式（VI）化合物及其药物组合物的微粒（例如，纳米颗粒），这些微粒具有穿透黏液的特性。还提供了使用这些化合物或药物组合物治疗疾病的方法。
• Therapeutic compounds and uses thereof
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US10285991B2

  公开（公告）日：2019-05-14

  Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and/or preventing diseases are also provided.

  本文描述了式 (I)-(III) 化合物、其药学上可接受的盐及其药物组合物。还提供了由式（I）-（III）化合物及其药物组合物组成的具有粘液渗透性的颗粒（如纳米颗粒）。还提供了使用这些化合物或其药物组合物治疗和/或预防疾病的方法。
• NADPH oxidase 4 inhibitors
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US11136317B2

  公开（公告）日：2021-10-05

  The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.

  本发明涉及式 (I) 的 2,5-二取代苯并恶唑和苯并噻唑衍生物 其中 L、X、Y 和环（A）如描述中所述，它们的制备及其作为药用活性化合物的用途。所述化合物可用于预防或治疗与活性氧（ROS）生成受损有关的疾病或紊乱，和/或预防或治疗各种纤维化疾病。
• 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP3310767B1

  公开（公告）日：2020-07-22
• Therapeutic Compounds and Uses Thereof
  申请人：KALA PHARMACEUTICALS, INC.

  公开号：US20160002254A1

  公开（公告）日：2016-01-07

  Described herein are compounds of Formula (I) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.